Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2013

View Archived Issues

Stimulation of developmental pathways to reverse structural and cognitive deficits in trisomy 21

Update on phase III investigation of a novel radiotracer for the detection of oral carcinoma

Phase II results presented for blosozumab, a monoclonal antibody targeting sclerostin

PDI and Transgenomic to commercialize the CardioPredict molecular diagnostic test

Seragon Pharmaceuticals raises funds to advance pipeline of cancer therapies

AAA reaches halfway recruitment milestone in phase III Lutathera trial

Hybrigenics acquires Imaxio's genomics division

Dance Biopharm forms joint venture with Harmony Asset for inhaled insulin

Zydus and Pieris enter alliance for novel Anticalin therapeutics

Phase I trial of KEA-0447/KRP-EPA605 for treatment of overactive bladder begins

U.S. DoD and MediVector set to advance anti-influenza drug to phase III

Nosopharm secures funding from French government to support development of new antibiotic class

Yale researchers begin trial of Halozyme's recombinant hyaluronidase in artificial pancreas

New drug combination for Parkinson's disease allows lower doses with enhanced clinical effects

Highly selective DPP IV inhibitor shows outstanding results in vivo

Merck KGaA patents TANK1/2 inhibitors

Incozen and Rhizen jointly report HGF receptor inhibitors

Novel BTK inhibitors described in Takeda patent

Canadian researchers design SH2 domain variants

Rebiotix begins phase II trial in recurrent Clostridium difficile-associated diarrhea

Omeros reports additional data from phase I OMS-824 program

Relypsa reports topline data from phase IIb trial of patiromer

Misodel vaginal delivery system approved for labor induction in Europe

Phase Ia VGX-100 trial completes patient enrollment

Studies support serum biomarker test to predict optimal treatment, long-term outcome in HF patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...